CL2015002311A1 - Derivado de piridina monocíclico - Google Patents

Derivado de piridina monocíclico

Info

Publication number
CL2015002311A1
CL2015002311A1 CL2015002311A CL2015002311A CL2015002311A1 CL 2015002311 A1 CL2015002311 A1 CL 2015002311A1 CL 2015002311 A CL2015002311 A CL 2015002311A CL 2015002311 A CL2015002311 A CL 2015002311A CL 2015002311 A1 CL2015002311 A1 CL 2015002311A1
Authority
CL
Chile
Prior art keywords
pyridine derivative
monocyclic pyridine
monocyclic
derivative
ilcarbonil
Prior art date
Application number
CL2015002311A
Other languages
English (en)
Inventor
Setsuo Funasaka
Toshimi Okada
Keigo Tanaka
Satoshi Nagao
Isao Ohashi
Yoshinobu Yamane
Yusuke Nakatani
Yuki KAROJI
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2015002311A1 publication Critical patent/CL2015002311A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de 5-({2-[(ARIL/HETEROARIL-2-ILCARBONIL)AMINO]PIRIDIN-4-IL}OXI)-1H-INDOL-1-carboxamida
CL2015002311A 2013-02-20 2015-08-18 Derivado de piridina monocíclico CL2015002311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361766922P 2013-02-20 2013-02-20

Publications (1)

Publication Number Publication Date
CL2015002311A1 true CL2015002311A1 (es) 2016-02-05

Family

ID=51351646

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002311A CL2015002311A1 (es) 2013-02-20 2015-08-18 Derivado de piridina monocíclico

Country Status (35)

Country Link
US (1) US8933099B2 (es)
EP (1) EP2960238B1 (es)
JP (2) JP5600229B1 (es)
KR (1) KR102050128B1 (es)
CN (1) CN105073730B (es)
AR (1) AR094812A1 (es)
AU (1) AU2014219811B2 (es)
BR (1) BR112015019790B1 (es)
CA (1) CA2901585C (es)
CL (1) CL2015002311A1 (es)
CY (1) CY1119220T1 (es)
DK (1) DK2960238T3 (es)
ES (1) ES2628495T3 (es)
HK (1) HK1215949A1 (es)
HR (1) HRP20170873T1 (es)
HU (1) HUE032931T2 (es)
IL (1) IL240623B (es)
JO (1) JO3261B1 (es)
LT (1) LT2960238T (es)
ME (1) ME02755B (es)
MX (1) MX361870B (es)
MY (1) MY178760A (es)
NZ (1) NZ711101A (es)
PE (1) PE20151509A1 (es)
PH (1) PH12015501813A1 (es)
PL (1) PL2960238T3 (es)
PT (1) PT2960238T (es)
RS (1) RS56064B1 (es)
RU (1) RU2645352C2 (es)
SG (1) SG11201506488WA (es)
SI (1) SI2960238T1 (es)
TW (4) TWI672296B (es)
UA (1) UA116794C2 (es)
WO (1) WO2014129477A1 (es)
ZA (1) ZA201505941B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102344105B1 (ko) * 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
MX2017009892A (es) * 2015-03-25 2017-11-15 Nat Cancer Ct Agente terapeutico contra el colangiocarcinoma.
US20180303817A1 (en) * 2015-12-17 2018-10-25 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
RU2020108284A (ru) * 2017-10-12 2021-11-12 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция, содержащая селективный ингибитор тирозинкиназы fgfr
MX2020008610A (es) 2018-03-28 2020-09-21 Eisai R&D Man Co Ltd Agente terapeutico para carcinoma hepatocelular.
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3180128A1 (en) * 2020-04-17 2021-10-21 Eisai R&D Management Co., Ltd. Breast cancer therapeutic agent
TW202220652A (zh) 2020-07-31 2022-06-01 日商衛材R&D企管股份有限公司 乳癌治療劑
EP4209216A1 (en) 2020-10-28 2023-07-12 Eisai R&D Management Co., Ltd Pharmaceutical composition for treating tumors
EP4361139A1 (en) * 2021-08-31 2024-05-01 Eisai R&D Management Co., Ltd. Production method for synthetic intermediate of monocyclic pyridine derivative
EP4361143A1 (en) 2021-08-31 2024-05-01 Eisai R&D Management Co., Ltd. Method for producing monocyclic pyridine derivative
WO2023174400A1 (zh) * 2022-03-18 2023-09-21 上海润石医药科技有限公司 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
ES2318649T3 (es) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
WO2002081420A1 (fr) 2001-04-03 2002-10-17 Eisai Co., Ltd. Derive de cyclooctanone et derive de cyclodecanone et utilisation de ces derives
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
NZ538617A (en) * 2002-08-30 2005-12-23 Eisai Co Ltd Azaarene derivatives
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
MXPA05010765A (es) 2003-04-10 2005-12-12 Hoffmann La Roche Compuestos pirimido.
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
ME00011A (me) 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
AU2007337895C1 (en) 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
WO2009001070A1 (en) 2007-06-25 2008-12-31 Qinetiq Limited Heater suitable for use in a preconcentrator device
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
CL2008003675A1 (es) * 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
WO2009076660A2 (en) * 2007-12-13 2009-06-18 Tyratech, Inc. Organic absorbent material and uses thereof
ES2554513T3 (es) 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
MX2010014234A (es) 2008-06-19 2011-03-25 Astrazeneca Ab Compuestos pirazol 436.
CA2748174A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
CN102325755B (zh) 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
AU2009335016A1 (en) 2008-12-30 2011-08-18 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
BR112012008094A2 (pt) 2009-08-07 2020-08-18 Chugai Seiyaku Kabushiki Kaisha derivado de aminopirazol, seu uso, composição farmacêutica que o compreende, agentes para inibir a atividade de fgfr e para prevenir ou tratar câncer
ES2524548T3 (es) 2009-10-30 2014-12-10 Novartis Ag N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
PL2657233T3 (pl) 2012-01-19 2015-01-30 Taiho Pharmaceutical Co Ltd 3,5-dipodstawiony związek alkinylobenzenowy i jego sól
AU2013227139B2 (en) 2012-02-28 2017-02-16 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
PT2872491T (pt) 2012-07-11 2021-08-05 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
TWI606066B (zh) 2012-09-27 2017-11-21 中外製藥股份有限公司 FGFR3 Fusion Gene and Its Targeted Medicine
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
CN105073730A (zh) 2015-11-18
RS56064B1 (sr) 2017-10-31
ES2628495T3 (es) 2017-08-03
US8933099B2 (en) 2015-01-13
MX2015010698A (es) 2016-04-11
MX361870B (es) 2018-12-18
EP2960238A4 (en) 2016-08-17
CA2901585A1 (en) 2014-08-28
AU2014219811B2 (en) 2017-09-28
TWI672139B (zh) 2019-09-21
PT2960238T (pt) 2017-06-05
AU2014219811A1 (en) 2015-09-03
CA2901585C (en) 2019-09-24
DK2960238T3 (en) 2017-06-26
JO3261B1 (ar) 2018-09-16
NZ711101A (en) 2018-08-31
UA116794C2 (uk) 2018-05-10
RU2645352C2 (ru) 2018-02-21
TW201900169A (zh) 2019-01-01
ME02755B (me) 2018-01-20
KR102050128B1 (ko) 2019-11-28
SG11201506488WA (en) 2015-09-29
SI2960238T1 (sl) 2017-07-31
PH12015501813A1 (en) 2015-12-07
TW201439085A (zh) 2014-10-16
LT2960238T (lt) 2017-07-10
IL240623A0 (en) 2015-10-29
WO2014129477A1 (ja) 2014-08-28
TW201902889A (zh) 2019-01-16
EP2960238B1 (en) 2017-04-05
CN105073730B (zh) 2017-10-13
PE20151509A1 (es) 2015-10-18
JPWO2014129477A1 (ja) 2017-02-02
TWI672296B (zh) 2019-09-21
BR112015019790A2 (pt) 2017-07-18
TWI672140B (zh) 2019-09-21
US20140235614A1 (en) 2014-08-21
TW201900168A (zh) 2019-01-01
IL240623B (en) 2019-03-31
KR20150118151A (ko) 2015-10-21
CY1119220T1 (el) 2018-02-14
JP2014237707A (ja) 2014-12-18
RU2015134558A (ru) 2017-03-24
PL2960238T3 (pl) 2017-09-29
HK1215949A1 (zh) 2016-09-30
EP2960238A1 (en) 2015-12-30
AR094812A1 (es) 2015-08-26
MY178760A (en) 2020-10-20
JP5600229B1 (ja) 2014-10-01
TWI641602B (zh) 2018-11-21
ZA201505941B (en) 2016-07-27
HRP20170873T1 (hr) 2017-09-08
HUE032931T2 (en) 2017-11-28
BR112015019790B1 (pt) 2020-12-01

Similar Documents

Publication Publication Date Title
CL2015002311A1 (es) Derivado de piridina monocíclico
DK3436444T3 (da) Heterocyklisk forbindelse
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
CR20150507A (es) Inhibidores de histona desmetilasas
DK3728252T3 (da) 4-azaindolforbindelser
BR112015027130A2 (pt) 5-(3,5-dimetilisoxazol-4-il)indolin-2-ona substituído
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
CL2015003031A1 (es) Compuesto peptídico
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UA30475S (uk) Футляр для електронних сигарет
DK3300610T3 (da) Fremgangsmåde til fraktionering af opløselige ærter
UY34654A (es) Inhibidores de la beta-secretasa
DK3672977T3 (da) Boronsyrederivater
DK3456344T3 (da) Proteiner, der er specifikke for baff og b7rp1, og anvendelser deraf
UY34807A (es) Derivados monocíclicos de heteroarilcicloalquil- diamina
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
DK2947066T3 (da) Phenoxyalkylaminforbindelse
BR112016003583A2 (pt) compostos herbicidas
CL2016000616A1 (es) Compuestos heterocíclicos de n-acilimino.
DK3080385T3 (da) Forbedret lukkeapparat
ES2784241T8 (es) Cinta de enmascarar
FR3006896B1 (fr) Composition photoprotectrice
FI20135274A (fi) Parannettu seurantajärjestelmä